News
TRVI
6.47
+1.89%
0.12
Weekly Report: what happened at TRVI last week (0421-0425)?
Weekly Report · 2d ago
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
TipRanks · 04/23 15:16
Trevi Therapeutics management to meet virtually with B. Riley
TipRanks · 04/21 13:56
Weekly Report: what happened at TRVI last week (0414-0418)?
Weekly Report · 04/21 10:58
Weekly Report: what happened at TRVI last week (0407-0411)?
Weekly Report · 04/14 10:49
Trevi Therapeutics management to meet with Cantor Fitzgerald
TipRanks · 04/11 15:35
Trevi Therapeutics Price Target Maintained With a $24.00/Share by Needham
Dow Jones · 04/08 12:36
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Clover Health Investments (CLOV) and Pacira Pharmaceuticals (PCRX)
TipRanks · 04/08 10:50
Trevi Therapeutics’ Haduvio: A Promising Therapy for IPF and RCC with Anticipated CORAL Trial Results
TipRanks · 04/08 06:05
Weekly Report: what happened at TRVI last week (0331-0404)?
Weekly Report · 04/07 10:49
Weekly Report: what happened at TRVI last week (0324-0328)?
Weekly Report · 03/31 10:58
Top Executive Offloads Trevi Therapeutics Shares!
TipRanks · 03/27 02:04
AVALO THERAPEUTICS APPOINTS MICHAEL HEFFERNAN AS CHAIRMAN OF THE BOARD
Reuters · 03/26 11:00
Weekly Report: what happened at TRVI last week (0317-0321)?
Weekly Report · 03/24 10:48
Trevi Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges
TipRanks · 03/22 00:15
Trevi Therapeutics Price Target Raised to $20.00/Share From $11.00 by B. Riley Securities
Dow Jones · 03/19 16:01
B. Riley Securities Reiterates Buy on Trevi Therapeutics, Raises Price Target to $20
Benzinga · 03/19 15:51
Trevi Therapeutics Is Maintained at Buy by Needham
Dow Jones · 03/19 11:49
Trevi Therapeutics Price Target Cut to $24.00/Share From $25.00 by Needham
Dow Jones · 03/19 11:49
Trevi Therapeutics Price Target Maintained With a $21.00/Share by D. Boral Capital
Dow Jones · 03/19 11:42
More
Webull provides a variety of real-time TRVI stock news. You can receive the latest news about Trevi Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.